Pharma Pipeline Optimization & Market Access Intelligence
Strengthen portfolio planning and pricing strategy with real-time intelligence on therapeutic pipelines, regulatory shifts, and competitive positioning.
5 Articles in Pharmaceuticals and Drug Development
GenAI in the Lab: Accelerating Drug Discovery Through Generative Molecular Design
GenAI in the Lab: Accelerating Drug Discovery Through Generative Molecular DesignThe process of drug invention has long been slow, difficult and costly, relying largely on trial and error. Time, expense and complexity have hindered success. GenAI is offering science a new creative partner, one who can do it with great accuracy, speed and intention.
Antihelminthic Drugs: Playing a Vital Role in Combating Parasitic Infections
Antihelminthic drug refers to medications designed to treat individuals afflicted with infections from parasitic worms, such as roundworms, tapeworms and flukes. These medications work by either disrupting the energy metabolism pathway or the neuromuscular function that causes worm paralysis or death, and ultimately, enabling the expulsion from the host.
Bioelectronic Medicine: Growing Interest in Nerve Stimulation Treatments
For years, people believed that there was a pill for every condition. However, contrary to the usual pattern, our bodies have always spoken a different dialect. It is not a language of substances but of electric signals, millions of tiny impulses that control cardiac function and the rhythm of respiration and ensure that every cell is synchronized.
Global Initiatives on AMR (Antimicrobial Resistance): What It Means for Pharma Pipelines and Future Markets?
The phenomenon of antimicrobial resistance (AMR) poses a significant threat to human health. It has been weakening the effectiveness of medicine over the past few years, posing a serious challenge to both human and animal healthcare systems.
Bioprinting of Human Microtissue for Drug Testing
Drug development faces pressure to become faster, more predictive, and more human-relevant. The core problem is the apparent limitations in the way we test medication candidates before human trials. The primary issue with traditional testing methods, including 2D cell cultures and animal experiments, is their inability to replicate the dynamic biological processes that occur in human bodies.
